Lifeward Ltd 2026年度季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). FORM 10-QFOR THE QUARTER ENDED MARCH 31, 2026TABLE OF CONTENTSPageNo.GENERAL AND WHERE YOU CAN FIND MORE INFORMATIONiiPART IFINANCIAL INFORMATIONF - 1ITEM1.FINANCIAL STATEMENTSF - 1CONDENSED CONSOLIDATED BALANCE SHEETS - MARCH 31, 2026 (unaudited) AND DECEMBER 31, 2025F - 1CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – THREE MONTHS ENDED MARCH 31, 2026AND 2025 (unaudited)F - 3CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY – MARCH 31, 2026 AND 2025(unaudited)F - 4CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – THREE MONTHS ENDED MARCH 31, 2026AND 2025 (unaudited)F - 5NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)F - 6ITEM2.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS1ITEM3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK9ITEM4.CONTROLS AND PROCEDURES9PARTIIOTHER INFORMATION10ITEM1.LEGAL PROCEEDINGS10ITEM1A.RISK FACTORS10ITEM2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS10ITEM3.DEFAULTS UPON SENIOR SECURITIES10ITEM4.MINE SAFETY DISCLOSURES10ITEM5.OTHER INFORMATION10ITEM6.EXHIBITS11SIGNATURES12 Introduction and Where You Can Find Other Information As used in this quarterly report on Form 10-Q (this “quarterly report”), the terms “Lifeward,” the “Company,” “LL,” “we,” “us” and “our”refer to Lifeward Ltd. and its subsidiaries, unless the context clearly indicates otherwise. Our website is www.golifeward.com. Informationcontained in, or that can be accessed through, our website does not constitute a part of this quarterly report and is not incorporated by referenceherein. We have included our website address in this quarterly report solely for informational purposes. Information that we furnish to or filewith the Securities and Exchange Commission (the “SEC”), including annual reports on Form 10-K, quarterly reports on Form 10-Q, current Special Note Regarding Forward-Looking Statements In addition to historical information, this quarterly report contains forward-looking statements within the meaning of Section 27A of theSecurities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “ExchangeAct”), and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our management’s beliefsand assumptions and on information currently available to our management. Forward- looking statements include information concerning ourpossible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potentialgrowth opportunities, potential market opportunities and the effects of competition. Forward-looking statements may include projectionsregarding our future performance and, in some cases, can be identified by words like “anticipate,” “assume,” “believe,” “could,” “seek,” •our expectations regarding future growth, including our ability to increase sales in our existing geographic markets and expand to newmarkets; •our ability to continue as a going concern for the next twelve months; •our ability to maintain and grow our reputation and the market acceptance of our products; •our ability to achieve reimbursement from third-party payors for Private, Governments, and Medicare & Medicaid Services (“CMS”)coverage for our products, including our ability to successfully submit and gain approval of cases for Medicare coverage through Medicare •our ability to successfully integrate Oratech Pharmaceuticals Ltd. into our organization, and realize the anticipated benefits therefrom; •the expected timing and results of the ORMD-0801 clinical trial; •our ability to have sufficient funds to meet certain future capital requirements, which could impair our efforts to develop and commercializeexisting and new products; •our ability to achieve expected operating efficiencies and sustain or improve operating expense reductions, and our ability to handle anybusiness disruptions that may occur in connection with streamlining operations; •our reliance on third-party contract manufacturers for the production of our AlterG Anti-Gravity Systems and our ability to maintain productquality, ensure timely production and delivery, and manage potential supply chain disruptions; •our ability to leverage our sales,